Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021
- PMID: 34937134
- PMCID: PMC8206820
- DOI: 10.1111/imj.15586
Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021
Abstract
Invasive fungal diseases (IFD) are serious infections associated with high mortality, particularly in immunocompromised patients. The prescribing of antifungal agents to prevent and treat IFD is associated with substantial economic burden on the health system, high rates of adverse drug reactions, significant drug-drug interactions and the emergence of antifungal resistance. As the population at risk of IFD continues to grow due to the increased burden of cancer and related factors, the need for hospitals to employ antifungal stewardship (AFS) programmes and measures to monitor and prevent infection has become increasingly important. These guidelines outline the essential components, key interventions and metrics, which can help guide implementation of an AFS programme in order to optimise antifungal prescribing and IFD management. Specific recommendations are provided for quality processes for the prevention of IFD in the setting of outbreaks, during hospital building works, and in the context of Candida auris infection. Recommendations are detailed for the implementation of IFD surveillance to enhance detection of outbreaks, evaluate infection prevention and prophylaxis interventions and to allow benchmarking between hospitals. Areas in which information is still lacking and further research is required are also highlighted.
Keywords: antifungal stewardship; hospital building work; infection prevention; invasive fungal disease; outbreak management; quality process.
© 2021 Royal Australasian College of Physicians.
References
-
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: e359-86.
-
- Pritzkuleit R, Beske F, Katalinic A. Demographic change and cancer. Onkologie 2010; 33 (Suppl 7): 19-24.
-
- Gross BN, Steib-Bauert M, Kern WV, Knoth H, Borde JP, Krebs S et al. Hospital use of systemic antifungal drugs: a multi-center surveillance update from Germany. Infection 2015; 43: 423-9.
-
- Ananda-Rajah MR, Cheng A, Morrissey CO, Spelman T, Dooley M, Neville AM et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrob Agents Chemother 2011; 55: 1953-60.
-
- Valentine JC, Morrissey CO, Tacey MA, Liew D, Patil S, Ananda-Rajah M. A population-based analysis of attributable hospitalisation costs of invasive fungal diseases in haematological malignancy patients using data linkage of state-wide registry and costing databases: 2009-2015. Mycoses 2020; 63: 162-71.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
